We propose a dual approach that combines PKCδ and BCR-ABL inhibition as very effective against both proliferative CML cells and progenitors, in association with any TKI available as first line treatment. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.